NLRP3 and cholestasis: Put together, these data suggest that VDR activation by calcipotriol alleviates liver fibrosis and injury in cholestasis through inhibition of NLRP3 signal, and calcipotriol inhibits HSC activation by inhibiting NLRP3 pathway both directly and indirectly.